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Background Treating myocardial infarction in the setting of immune thrombocytopenic purpura (ITP) is always a challenge espe-
cially if the platelet count is labile. Cardiologists dealing with such patients should keep a delicate balance between
thrombotic and bleeding complications.
...................................................................................................................................................................................................
Case summary A 50-year-old gentleman with treatment-challenging ITP presented with acute inferior ST elevation myocardial in-
farction after receiving recent intravenous immunoglobulin. Using optical coherence tomography (OCT) guidance,
it was decided to treat him with percutaneous old balloon angioplasty especially with the labile nature of his plate-
let count. Subsequently, dual antiplatelet therapy was a challenge and he remained on clopidogrel for a period of
only 10 weeks.
...................................................................................................................................................................................................
Conclusion This case highlights the rare presentation of patients with ITP with thrombotic complications and the usefulness of
OCT in formulating a management plan.
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Learning points
• Intracoronary imaging with optical coherence tomography can help guide percutaneous coronary intervention strategy in challenging cases,
and plain old balloon angioplasty can be safe and effective in some cases.
• Patients with immune thrombocytopenic purpura can present with acute coronary syndromes especially after intravenous immunoglobulin
therapy carrying the risk of both bleeding and thrombosis. Treatment should be individually tailored.
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Immune thrombocytopenic purpura (ITP) is a disease causing auto-
immune destruction of platelets and suppression of platelets produc-
tion. Its incidence in adults is 3.3/100 000 adults per year and the
prevalence is 9.5/100 000 adults. The disease affects more females
than males in young adults but after the age of 65, there is no sex pre-
dilection.1 Mortality is higher among ITP patients than normal popula-
tion.2 Although ITP patients present mainly with mucocutaneous
bleeding, they are at a higher risk of thrombotic cardiovascular
events.3 This makes managing them a real challenge. As regards to
percutaneous coronary intervention, a difficult decision needs to be
made as whether to put a stent or not as in-stent thrombosis has
mortality of 17-45%.4 Here we present a patient with difficult-to-
treat ITP presenting with acute coronary syndromes (ACS) and




50-year-old gentleman, an ex-smoker with background of hyper-
tension and obesity, presented with inferior ST-segment elevation
myocardial infarction. Eight years earlier, he was diagnosed with
ITP, which was difficult to treat despite immunosuppressive agents
due to highly labile platelets count (PC). Apart from thrombo-
cytopenia, his complete blood count was normal in addition to
routine biochemical profile, lactate dehydrogenase level, autoanti-
bodies levels, and immunoglobulins. He was negative for hepatitis
profile and human immunodeficiency virus. He was on daily 75 mg
of Eltrombopag (RevoladeVR Novartis), a small molecule agonist of
thrombopoietin receptor, with occasional dexamethasone rescue
therapy. Unfortunately, he developed sepsis and petechiae affect-
ing his lower limbs and was admitted in our hospital. His PC was
2  109/L (normal range 150–400  109/L) and he received intra-
venous immunoglobulin (IVIG). He was discharged home but on
Day 7 post-IVIG initiation, presented with acute chest pain for 3 h
and electrocardiogram confirming ST-elevation in the inferior
leads (Figure 1). He was haemodynamically stable and cardiovascu-
lar examination was normal. His PC was 658  109/L, haemoglo-
bin 13.4 g/dL (13–16.2 g/dL) and white blood count 9.3  109/L
(normal range 4.3–11.2  109/L). He was given 300 mg of aspirin
and clopidogrel. Radial coronary angiogram showed critical prox-
imal stenosis in the right coronary artery (RCA) with TIMI 2 flow
(Figure 2A). Additionally, there was mild distal left main stem dis-
ease with moderate proximal left anterior descending artery dis-
ease, and mild lesion in proximal circumflex artery. A bolus of
1000 IU of heparin was given with the aim to achieve activated
clotting time of 250–300 s. A 2.5  15 mm balloon was inflated
to improve flow. The lesion was further assessed with OCT
which showed proximal atheroma with plaque erosion and red
thrombus (Figure 3A). A 4.0  15 mm balloon was then inflated
to low pressure at the lesion, no stents were deployed and TIMI
3 flow was restored (Figure 2B). Optical coherence tomography
analysis was re-done, and did not reveal any significant dissections
(Figure 3B). Laboratory tests post-procedure showed high
sensitivity-Troponin I level of 6444 ng/L (normal <34 ng/L), with
normal lipid profile. After consultation with the haematologist,
both aspirin and clopidogrel were continued with the addition of
lansoprazole to reduce the risk of upper gastrointestinal bleeding.
Echocardiogram post-percutaneous coronary intervention (PCI)
showed normal left ventricular ejection fraction (55%).
Eltrombopag was paused due to the thrombocytosis and restarted
12 days later during an outpatient visit due to symptomatic drop
in PC to 3  109/L. Clopidogrel was stopped, aspirin continued,
and a short course of dexamethasone started. When the PC rose
above 30  109/L, clopidogrel was restarted and given for a total
of 10 weeks before discontinuing it completely due to a fall in PC
from 162 to 49  109/L. One year later, aspirin was stopped as
PC decreased to 1  109/L with occurrence of spontaneous
bruises. The patient has remained angina-free so far.
Discussion
Platelets play a major role in the pathogenesis of atherosclerosis-
related coronary artery disease and other thrombotic conditions.
However, it is well known that thrombocytopenia does not give im-
munity against such conditions.4 There have been several case
reports of patients with thrombocytopenia associated with various
illnesses such as cancers, hereditary thrombocytopenias, ITP, etc.
who also got ACS. In case of ITP, there are several proposed mecha-
nisms for this phenomenon such as the formation of young platelets
which are large and more adhesive, and rising level of platelets micro-
particles which are highly thrombogenic. Also, it is well-known that
IVIG increases blood viscosity and this makes patients with ITP prone
to ACS especially with incremental PC which can happen up to
8 days post-infusion.5 Our patient developed MI 7 days after initiating
IVIG with a PC of 658 109/L.
Treatment of such patients poses a challenge due to the rarity of
the problem, lack of evidence, and limited guidelines. The main two
points facing any cardiologist treating this condition is how to tailor
antiplatelets therapy and what is the best interventional strategy.
As far as dual antiplatelets therapy (DAPT) is concerned, it seems
it is a safe approach if PC remains more than 30 109/L and the pa-
tient is not bleeding.6 Regarding the choice of antiplatelets, we pro-
pose aspirin and clopidogrel as clopidogrel has fewer bleeding
complications compared with other P2Y12 inhibitors.
Day 0 Worsening bleeding complications and platelet count of
2  109 requiring intravenous immunoglobulin
Day 7 Inferior ST-elevation myocardial infarction and plain old
balloon angioplasty to right coronary artery guided by
optical coherence angioplasty
Week 10 Dual antiplatelets therapy interrupted due to symptom-
atic drop in platelet count
1 year Patient continues to be chest pain free





..Percutaneous coronary intervention in patients with low PC lacks
evidence and thrombolysis is contraindicated. Radial approach is pre-
ferred due to reduced bleeding complications as compared with
femoral approach. In most cases, bare metal stent (BMS) was used to
reduce the duration of DAPT.7 A study published in 2015 suggested
the use of polymer-free drug-coated coronary stents (such as
Figure 1 Electrocardiogram showing ST-elevation in the inferior leads.
Figure 2 (A) Coronary angiogram showing thrombotic lesion in proximal right coronary artery (white arrow). (B) Final angiographic result in right
coronary artery with stenotic segment open (yellow arrow).





























BioFreedom stent) might be better than BMSs because of less rate
of restenosis and target-lesion revascularization with same duration
of DAPT.8 The problem with that study is that it defined thrombo-
cytopenia as PC < 100  109/L without mentioning the minimum
number. Furthermore, bleeding rate was high (7.2%) and majority
of the study population were regarded as being at high risk of
bleeding solely because of advanced age. Moreover, there is no
long-term safety outcome data for that stent beyond 390 days with
regards to stent thrombosis, myocardial infarction, or cardiac death.
With regards to drug-coated balloon, evidence in large coronary
arteries of 4 mm is limited though it has been successful in arteries
with 3 mm diameter.9 Moreover, it requires more aggressive lesion
preparation with pre-dilatation having a balloon-to-vessel ratio of
0.8–1.0.10 This increases the risk of dissection mandating stent im-
plantation, the thing we were trying to avoid. We used percutan-
eous old balloon angioplasty because it gave us the flexibility to
discontinue DAPT if PC dropped. This happened to our patient on
Day 12 necessitating withdrawal of clopidogrel. One of the major
disadvantages of percutaneous old balloon angioplasty is the recur-
rence of stenosis in the treated segment. This is largely driven by a
high incidence of post-angioplasty dissection especially when the
vessel lumen is narrow. In our case, the lumen diameter was
4.0 mm. To ensure that there is no dissection, we used OCT that
(besides confirming the diagnosis and showing the atherosclerotic
nature of the stenosis) demonstrated only minimal dissection.
Furthermore, the images were consistent with plaque erosion ra-
ther than rupture with no calcification. This further reduced the
risk of clinically significant acute recoil. Based on this, we decided
not to implant a stent. We identified three case reports for the use
of plain balloon angioplasty in patients with ITP and acute MI.11–13
No intracoronary imaging used in two cases and Re-infarction
occurred 9 h after PCI in one case. The most recent report used
intravascular ultrasound. We are the first to report use of OCT in
such patients. Finally, non-interventional, stent-less approach with
only DAPT might be considered based on the EROSION study.14
However, it is a small, non-randomized, and single-centre study that
was not powered for the clinical endpoint. It also did not include
ITP patients in whom such strategy might be harmful.
Conclusion
This case highlights the risk of developing a major thrombotic event
in patients with ITP especially after IVIG therapy. Our case is unique
in that we are the first, to our knowledge, to report successful use of
OCT to guide treatment in a patient with severe thrombocytopenia
and ACS with a very good clinical result.
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Figure 3 (A) Optical coherence tomography showing red thrombus overlying lipidic plaque with evidence of plaque erosion (white arrow). (B)















































































































Supplementary material is available at European Heart Journal - Case
Reports online.
Slide sets: A fully edited slide set detailing this case and suitable for
local presentation is available online as Supplementary data.
Consent: The authors confirm that written consent for submission
and publication of this case report including images and associated
text has been obtained from the patient in line with COPE guidance.
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